Get started
Author

Jaques Mordoukh

Observed name: Jacques Mordoukh
ORCID: 0009-0002-5987-0716
Observed ORCID: 0009-0002-5987-0716
OpenAlex ID: A5139798366
Figure 1 from Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma
2026 · Nurit Gal-Mark, Assaf Grunwald, et al.
Supplementary Table S2 from Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma
2026 · Nurit Gal-Mark, Assaf Grunwald, et al.
Supplementary Figure S3 from Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma
2026 · Nurit Gal-Mark, Assaf Grunwald, et al.
Supplementary Figure S1 from Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma
2026 · Nurit Gal-Mark, Assaf Grunwald, et al.
Data from Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma
2026 · Nurit Gal-Mark, Assaf Grunwald, et al.
Figure 2 from Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma
2026 · Nurit Gal-Mark, Assaf Grunwald, et al.
Figure 3 from Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma
2026 · Nurit Gal-Mark, Assaf Grunwald, et al.
Supplementary Table S4 from Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma
2026 · Nurit Gal-Mark, Assaf Grunwald, et al.
Supplementary Table S3 from Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma
2026 · Nurit Gal-Mark, Assaf Grunwald, et al.
Supplementary Figure S6 from Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma
2026 · Nurit Gal-Mark, Assaf Grunwald, et al.
Supplementary Table S6 from Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma
2026 · Nurit Gal-Mark, Assaf Grunwald, et al.
Supplementary Figure S2 from Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma
2026 · Nurit Gal-Mark, Assaf Grunwald, et al.
Supplementary Table S5 from Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma
2026 · Nurit Gal-Mark, Assaf Grunwald, et al.
Supplementary Table S11 from Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma
2026 · Nurit Gal-Mark, Assaf Grunwald, et al.
Supplementary Figure S4 from Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma
2026 · Nurit Gal-Mark, Assaf Grunwald, et al.
Supplementary Table S9 from Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma
2026 · Nurit Gal-Mark, Assaf Grunwald, et al.
Supplementary Table S8 from Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma
2026 · Nurit Gal-Mark, Assaf Grunwald, et al.
Supplementary Table S1 from Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma
2026 · Nurit Gal-Mark, Assaf Grunwald, et al.
Supplementary Figure S5 from Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma
2026 · Nurit Gal-Mark, Assaf Grunwald, et al.
Supplementary Table S10 from Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma
2026 · Nurit Gal-Mark, Assaf Grunwald, et al.
Supplementary Table S7 from Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma
2026 · Nurit Gal-Mark, Assaf Grunwald, et al.
Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma
2026 · Nurit Gal-Mark, Assaf Grunwald, et al. · Clinical Cancer Research
Works count: 22
Citation count:
H-index:
I10-index:
Year
Topic
Type